Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Sweeney S., Ward Z., Platt L. et al.
Addiction: on-line advance publication, 2019.
What would happen to rates of infection with hepatitis C if we closed down all the needle exchanges? In three UK municipalities, the answers were predicted to be more infections, lost low-cost opportunities to improve and save lives, and in two of the areas, greater health-related costs overall. Conclusion was that these services are among the best investments UK health services can make. town
STUDY 2019 HTM file
Impact of the introduction and withdrawal of financial incentives on the delivery of alcohol screening and brief advice in English primary health care: an interrupted time-series analysis
O’Donnell A., Angus C., Hanratty B. et al.
Addiction: 2019, early view online.
The clearest impact of financial incentives to screen primary care patients in England was the plummeting screening rate after the incentives were withdrawn. If these results are applicable to England as a whole, over the following 21 months withdrawing the payments resulted in 603,719 fewer patients being screened for risky drinking and 27,439 fewer receiving brief advice.
REVIEW 2019 HTM file
Supervised consumption sites: a nuanced assessment of the causal evidence
Caulkins J.P., Pardo B., Kilmer B.
How high should the evidence bar be set when deciding whether to endorse drug consumption rooms?
Irvine M.A., Kuo M., Buxton J.A. et al.
Addiction: 2019, 114, p. 1602–1613.
[Consultation draft subject to amendment and correction.] In a Canadian region that declared a public health emergency over a rapid increase in drug overdoses, to what degree were three key substance use interventions saving lives? Study shows what actually happened and what would have happened in the absence of take-home naloxone, opioid substitution therapy, and drug consumption rooms.
Greenmyer J.R., Popova S., Klug M.G. et al.
Addiction: 2019, 115, p. 409–417.
[Consultation draft subject to amendment and correction.] A thorough review suggests that the expansion of prevention strategies for fetal alcohol spectrum disorder – prioritising those at the highest risk – would be a worthwhile social and economic investment in Canada and the United States.
Hickman M., Steer C., Tilling K. et al.
Addiction: 2018, 113(8), p. 1461–1476.
Buprenorphine may be associated with a lower risk of mortality than methadone among people engaged in opioid substitution treatment – but is the pattern of short treatment duration in the UK preventing maximal impact at a population level?
Rose A.K., Jones A.
Addiction: 2018, 113(8), p. 1396–1406.
With patchy evidence of the effectiveness of baclofen, and serious concerns about the medication’s safety, is it ‘premature’ for the muscle-relaxant to be prescribed as a treatment for alcohol use disorders?
STUDY 2018 HTM file
Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings – what is required to achieve the WHO’s HCV elimination targets?
Ward Z., Platt L., Sweeney S. et al.
Addiction: 2018, 113, p. 1727–1738.
What would it take for the UK to meet the World Health Organization’s target of a 90% reduction in hepatitis C by 2030? According to projections in three diverse areas, current levels of harm reduction services are averting a great deal of transmission, and adding only moderate rates of treatment for hepatitis C would put Britain on course to achieve the elimination target.
Jones A., Pierce M., Sutton M. et al.
Addiction: 2017, 113(2), p. 279–286.
Substance use treatment commissioned on a payment-by-results basis in England has been linked to higher rates of in-treatment abstinence and non-injecting than other commissioning models, but lower rates of treatment initiation and completion. Is this enough to support the policy?
REVIEW 2017 HTM file
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate
Palpacuer C., Duprez R., Huneau A. et al.
Addiction: 2017, in press.
In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification, extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none was there high quality evidence.
Select search results pageNEXT 1 2 3 4 5 6 7 8